Results 71 to 80 of about 36,891 (208)

Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment

open access: yesJournal of Tehran University Heart Center, 2019
Apixaban was introduced in clinical use for nonvalvular atrial fibrillation as an alternative to warfarin. There is a dearth of information regarding apixaban use in patients suffering from atrial fibrillation with intracardiac foreign bodies such as ...
Adem Adar, Orhan Önalan, Fahri Cakan
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

open access: yesJournal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga   +11 more
doaj   +1 more source

Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:Contemporary findings in real-life Danish patients [PDF]

open access: yes, 2017
Background The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding ...
Evans, David   +8 more
core   +3 more sources

Insights from a six‐year hair drug analysis compendium in drug‐facilitated crimes involving vulnerable population cases

open access: yesJournal of Forensic Sciences, EarlyView.
Abstract Hair analysis is a well‐established matrix in forensic toxicology, offering a valuable alternative or complement to traditional matrices in diverse contexts, including drug‐facilitated crimes (DFC), elder abuse, and accidental exposure in children.
Amandine Fort   +8 more
wiley   +1 more source

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

open access: yesJournal of Comparative Effectiveness Research, 2023
Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or ...
Josep Comin Colet   +6 more
doaj   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi   +8 more
wiley   +1 more source

APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE

open access: yesАтеротромбоз, 2017
Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
O. O. Shakhmatova, E. P. Panchenko
doaj   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen   +3 more
wiley   +1 more source

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

open access: yesClinical Pharmacology: Advances and Applications, 2013
Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global ...
Upreti VV   +7 more
doaj  

Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

open access: yesPLoS ONE, 2013
Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings.
Gines Escolar   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy